Gsk (GSK) Change in Accured Expenses (2009 - 2026)

Gsk's Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$1.0 billion for Q4 2016.

• In Q4 2016, Change in Accured Expenses fell 219.84% year-over-year to -$1.0 billion; the TTM figure through Dec 2016 stood at $607.6 million (down 82.91% YoY), while the FY2018 annual figure was $3.2 billion, up 40.65% from the prior year.
• Change in Accured Expenses for Q4 2016 stood at -$1.0 billion, down from $246.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 billion in Q4 2014, with the low at -$1.0 billion in Q4 2016.
• The 5-year median for Change in Accured Expenses is $300.0 million (2016), against an average of $87.9 million.
• The sharpest annual moves came in 2014 and 2016: Change in Accured Expenses soared 200.84% in 2014, then slumped 219.84% in 2016.
• Gsk's Change in Accured Expenses stood at -$864.0 million in 2012, then soared by 173.65% to $636.3 million in 2013, then jumped by 73.8% to $1.1 billion in 2014, then decreased by 22.61% to $855.9 million in 2015, then slumped by 219.84% to -$1.0 billion in 2016.
• Business Quant data shows GSK's Change in Accured Expenses at -$1.0 billion in Q4 2016, $246.5 million in Q1 2016, and $855.9 million in Q4 2015.